Showing 101 - 120 results of 472 for search '"The University of Minnesota"', query time: 0.07s Refine Results
  1. 101
  2. 102
  3. 103
  4. 104
  5. 105
  6. 106
  7. 107
  8. 108
  9. 109
  10. 110
  11. 111
  12. 112
  13. 113
  14. 114
  15. 115
  16. 116
  17. 117
  18. 118
  19. 119
  20. 120

    Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era by Ayotola Fatola, Michael D. Evans, Jenna Brown, Elizabeth Davis, Andrew Johnson, Ana G. Antun, Andrew M. Farland, Ryan Woods, Ara Metjian, Yara A. Park, Gustaaf de Ridder, Briana Gibson, Raj S. Kasthuri, Darla K. Liles, Susan Eubanks, Frank Akwaa, Todd Clover, Lisa Baumann Kreuziger, J. Evan Sadler, Meera Sridharan, Ronald S. Go, Keith R. McCrae, Harsh Vardhan Upreti, Ming Y. Lim, Nicole K. Kocher, Radhika Gangaraju, X. Long Zheng, Jay S. Raval, Camila Masias, Spero R. Cataland, Marshall Mazepa, Shruti Chaturvedi

    Published 2025-01-01
    “…Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the second or subsequent rituximab-treated episode than the first (2.1 vs 6.0 years; P = .04). …”
    Get full text
    Article